Healthy volunteers test new immune globulin injection method
NCT ID NCT06935266
First seen Nov 03, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This early-phase trial tested how well healthy adults tolerate TAK-881, a combination of immune globulin and hyaluronidase given as an injection under the skin. Sixty-four participants received different dosing schedules to see if the infusion could be completed without interruption due to side effects. The study is already completed and focused on safety and tolerability, not on treating any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion
Tempe, Arizona, 85283, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-881 (immune globulin with hyaluronidase)
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.